Author: admin

DelveInsight’s “Castrate-resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Castrate-resistant Prostate Cancer, historical and forecasted epidemiology as well as the Castrate-resistant Prostate Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Castrate-resistant Prostate Cancer, offering comprehensive insights into the Castrate-resistant Prostate Cancer revenue trends, prevalence, and treatment landscape. The report delves into key Castrate-resistant Prostate Cancer statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Castrate-resistant Prostate Cancer therapies. Additionally, we cover the landscape of Castrate-resistant Prostate Cancer clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Castrate-resistant Prostate Cancer treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Castrate-resistant Prostate Cancer space.

To Know in detail about the Castrate-resistant Prostate Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Castrate-resistant Prostate Cancer Market Forecast

Some of the key facts of the Castrate-resistant Prostate Cancer Market Report:

• The Castrate-resistant Prostate Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In September 2024, Ipsen reported that the Phase III CONTACT-02 trial evaluating Cabometyx and atezolizumab for metastatic castration-resistant prostate cancer (mCRPC) demonstrated a non-significant improvement in overall survival but successfully met the progression-free survival (PFS) endpoint.

• In August 2024, Nuvation Bio announced that the U.S. Food and Drug Administration has approved its investigational new drug application to assess NUV-1511, the first clinical candidate from the company’s innovative drug-drug conjugate (DDC) platform.

• In July 2024, The FDA has awarded fast-track designation to SYNC-T SV-102 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

• Key Castrate-resistant Prostate Cancer Companies: Janssen Research & Development, Pfizer, Astellas Pharma, Bristol-Myers Squibb, Laekna Therapeutics, Novartis, Hinova, AstraZeneca, Effector Therapeutics, Hinova pharmaceuticals, POINT Biopharma, Exelixis, Tavanta Therapeutics, Pfizer, Zenith Epigenetics, Surface Oncology, Opna-IO LLC, Taiho oncology, Arvinas, Forma therapeutics, ESSA Pharma, Oncternal, Janux Therapeutics, and others.

• Key Castrate-resistant Prostate Cancer Therapies: Niraparib, Talzenna, Opdivo (nivolumab), LAE001, 177Lu-PSMA617, HC-1119, AZD4635, tomivosertib (eFT508), Enzalutamide, and others

• The Castrate-resistant Prostate Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Castrate-resistant Prostate Cancer pipeline products will significantly revolutionize the Castrate-resistant Prostate Cancer market dynamics.

• Prostate cancer is the third most prevalent type of cancer in the US and the fourth most common worldwide. Approximately 1 in 9 men in the US will be diagnosed with prostate cancer at some point in their lives

• The total diagnosed cases of CRPC in the 7MM were found to be 2,692,615 in 2021 which is expected to grow during the study period

• The total prevalent cases of prostate cancer in the 7MM were observed to be 7,726,394 cases in 2021 which is expected to grow during the study period (2019–2032). In total prevalent cases of the 7MM; the US accounted for highest number of cases which were 3,581,872 cases in 2021

• Among the EU-5 countries, Germany had the highest diagnosed prevalence of Prostate Cancer, followed by France and Italy. On the other hand, Spain had the lowest diagnosed prevalent population in2021. Furthermore, in total diagnosed cases of the7MM; Japan accounted for 252,141cases of in 2021

Castrate-resistant Prostate Cancer Overview

Castrate-resistant prostate cancer (CRPC) is a type of prostate cancer that continues to grow and progress despite low levels of testosterone, typically achieved through androgen deprivation therapy (ADT). Initially, prostate cancer is often responsive to treatments that reduce testosterone, but over time, some cancer cells adapt and become resistant to these therapies. CRPC can manifest with rising prostate-specific antigen (PSA) levels, new symptoms, or metastasis. It is associated with a more aggressive disease course and requires alternative treatment strategies, such as chemotherapy, novel hormonal therapies, or targeted therapies, to manage the condition.

Get a Free sample for the Castrate-resistant Prostate Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/castrate-resistant-prostate-cancer-market

Castrate-resistant Prostate Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Castrate-resistant Prostate Cancer Epidemiology Segmentation:

The Castrate-resistant Prostate Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Castrate-resistant Prostate Cancer

• Prevalent Cases of Castrate-resistant Prostate Cancer by severity

• Gender-specific Prevalence of Castrate-resistant Prostate Cancer

• Diagnosed Cases of Episodic and Chronic Castrate-resistant Prostate Cancer

Download the report to understand which factors are driving Castrate-resistant Prostate Cancer epidemiology trends @ Castrate-resistant Prostate Cancer Epidemiology Forecast

Castrate-resistant Prostate Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Castrate-resistant Prostate Cancer market or expected to get launched during the study period. The analysis covers Castrate-resistant Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Castrate-resistant Prostate Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Castrate-resistant Prostate Cancer Therapies and Key Companies

• Niraparib: Janssen Research & Development

• Talzenna: Pfizer/Astellas Pharma

• Opdivo (nivolumab): Bristol-Myers Squibb

• LAE001: Laekna Therapeutics

• 177Lu-PSMA617: Novartis

• HC-1119: Hinova

Discover more about therapies set to grab major Castrate-resistant Prostate Cancer market share @ Castrate-resistant Prostate Cancer Treatment Landscape

Castrate-resistant Prostate Cancer Market Drivers

• Rising Geriatric Population and High Prevalence Rate of Castrate-resistant Prostate Cancer

• Increase in Demand for Castrate-resistant Prostate Cancer Treatment

• Products Surge in Awareness Regarding the Treatment of Castrate-resistant Prostate Cancer

• Innovation in drugs and developments in genomics and proteomics

Castrate-resistant Prostate Cancer Market Barriers

• Cost Constraints

• The Complex issue of Companion Diagnostics

• Entry Barrier

• Diagnostic challenges

Scope of the Castrate-resistant Prostate Cancer Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Castrate-resistant Prostate Cancer Companies: Janssen Research & Development, Pfizer, Astellas Pharma, Bristol-Myers Squibb, Laekna Therapeutics, Novartis, Hinova, AstraZeneca, Effector Therapeutics, Hinova pharmaceuticals, POINT Biopharma, Exelixis, Tavanta Therapeutics, Pfizer, Zenith Epigenetics, Surface Oncology, Opna-IO LLC, Taiho oncology, Arvinas, Forma therapeutics, ESSA Pharma, Oncternal, Janux Therapeutics, and others

• Key Castrate-resistant Prostate Cancer Therapies: Niraparib, Talzenna, Opdivo (nivolumab), LAE001, 177Lu-PSMA617, HC-1119, AZD4635, tomivosertib (eFT508), Enzalutamide, and others

• Castrate-resistant Prostate Cancer Therapeutic Assessment: Castrate-resistant Prostate Cancer current marketed and Castrate-resistant Prostate Cancer emerging therapies

• Castrate-resistant Prostate Cancer Market Dynamics: Castrate-resistant Prostate Cancer market drivers and Castrate-resistant Prostate Cancer market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Castrate-resistant Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Castrate-resistant Prostate Cancer Market Access and Reimbursement

To know more about Castrate-resistant Prostate Cancer companies working in the treatment market, visit @ Castrate-resistant Prostate Cancer Clinical Trials and Therapeutic Assessment

Table of Contents

1. Castrate-resistant Prostate Cancer Market Report Introduction

2. Executive Summary for Castrate-resistant Prostate Cancer

3. SWOT analysis of Castrate-resistant Prostate Cancer

4. Castrate-resistant Prostate Cancer Patient Share (%) Overview at a Glance

5. Castrate-resistant Prostate Cancer Market Overview at a Glance

6. Castrate-resistant Prostate Cancer Disease Background and Overview

7. Castrate-resistant Prostate Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Castrate-resistant Prostate Cancer

9. Castrate-resistant Prostate Cancer Current Treatment and Medical Practices

10. Castrate-resistant Prostate Cancer Unmet Needs

11. Castrate-resistant Prostate Cancer Emerging Therapies

12. Castrate-resistant Prostate Cancer Market Outlook

13. Country-Wise Castrate-resistant Prostate Cancer Market Analysis (2019–2032)

14. Castrate-resistant Prostate Cancer Market Access and Reimbursement of Therapies

15. Castrate-resistant Prostate Cancer Market Drivers

16. Castrate-resistant Prostate Cancer Market Barriers

17. Castrate-resistant Prostate Cancer Appendix

18. Castrate-resistant Prostate Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Castrate-resistant Prostate Cancer Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Janssen R&D, Pfizer, Astellas Pharma, Bristol-Myers Squibb, Laekna Therapeutics

DelveInsight’s “EGFR Inhibitors-Induced Skin Disorders Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the EGFR Inhibitors-Induced Skin Disorders, historical and forecasted epidemiology as well as the EGFR Inhibitors-Induced Skin Disorders market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the EGFR Inhibitors-Induced Skin Disorders market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; EGFR Inhibitors-Induced Skin Disorders Market Forecast

Some of the key facts of the EGFR Inhibitors-Induced Skin Disorders Market Report:

• The EGFR Inhibitors-Induced Skin Disorders market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In October 2024, Lutris Pharma completed patient enrollment in its Phase II clinical trial of LUT014, a novel B-Raf inhibitor for topical use aimed at treating acneiform rash caused by epidermal growth factor receptor (EGFR) inhibitor therapy. The study enrolled 117 patients with metastatic colorectal cancer (mCRC) who developed Grade 2 or non-infected Grade 3 acneiform rash induced by EGFR inhibitors.

• In February 2024, The US FDA awarded Orphan Drug Designation (ODD) to LUT014 for addressing EGFR inhibitor-induced acneiform rash.

• In January 2023, The FDA approved an investigational new drug (IND) application for HT-001, aiming to treat rash and skin disorders linked with EGFR inhibitor therapy.

• In 2023, the United States had the highest proportion of patients affected by EGFR inhibitor-induced skin disorders among the 7MM.

• In 2023, around 13,000 instances of EGFR inhibitor-induced skin disorders were reported among NSCLC cases in the United States.

• EGFR is mutated in 3.22% of colorectal carcinoma patients, with EGFR mutations occurring in 2.33% of all colorectal carcinoma cases.

• Key EGFR Inhibitors-Induced Skin Disorders Companies: Lutris Pharma, Hoth Therapeutics, TWi Biotechnology, Inc., and others

• Key EGFR Inhibitors-Induced Skin Disorders Therapies: LUT-014, HT-001, AC-701 Topical Gel 0.3%, and others

• The EGFR Inhibitors-Induced Skin Disorders market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage EGFR Inhibitors-Induced Skin Disorders pipeline products will significantly revolutionize the EGFR Inhibitors-Induced Skin Disorders market dynamics.

EGFR Inhibitors-Induced Skin Disorders Overview

EGFR inhibitors-induced skin disorders refer to dermatological side effects caused by medications that inhibit the epidermal growth factor receptor (EGFR). These drugs are commonly used in the treatment of various cancers, including lung, colorectal, and head and neck cancers. Skin-related adverse effects are among the most common side effects of EGFR inhibitors and can include rash, acneiform eruptions, dry skin, pruritus (itching), and paronychia (inflammation around the nails).

Get a Free sample for the EGFR Inhibitors-Induced Skin Disorders Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/egfr-inhibitors-induced-skin-disorders-market

EGFR Inhibitors-Induced Skin Disorders Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

EGFR Inhibitors-Induced Skin Disorders Epidemiology Segmentation:

The EGFR Inhibitors-Induced Skin Disorders market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of EGFR Inhibitors-Induced Skin Disorders

• Prevalent Cases of EGFR Inhibitors-Induced Skin Disorders by severity

• Gender-specific Prevalence of EGFR Inhibitors-Induced Skin Disorders

• Diagnosed Cases of Episodic and Chronic EGFR Inhibitors-Induced Skin Disorders

Download the report to understand which factors are driving EGFR Inhibitors-Induced Skin Disorders epidemiology trends @ EGFR Inhibitors-Induced Skin Disorders Epidemiology Forecast

EGFR Inhibitors-Induced Skin Disorders Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the EGFR Inhibitors-Induced Skin Disorders market or expected to get launched during the study period. The analysis covers EGFR Inhibitors-Induced Skin Disorders market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the EGFR Inhibitors-Induced Skin Disorders Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

EGFR Inhibitors-Induced Skin Disorders Therapies and Key Companies

• LUT-014: Lutris Pharma

• HT-001: Hoth Therapeutics

• AC-701 Topical Gel 0.3%: TWi Biotechnology, Inc.

Discover more about therapies set to grab major EGFR Inhibitors-Induced Skin Disorders market share @ EGFR Inhibitors-Induced Skin Disorders Treatment Landscape

EGFR Inhibitors-Induced Skin Disorders Market Strengths

• The rising incidence of cancer patients and access to anti-EGFR treatment over the globe increase chances of occurrence of EGFR inhibitor-induced skin disease and thus the surge in treatment options.

• Emergence of several novel therapy is expected to fuel the market growth.

EGFR Inhibitors-Induced Skin Disorders Market Opportunities

• Limited approved treatment options offer a great opportunity for the investment and development of novel therapies.

• Medications with better safety, effectiveness, and patient compliance are the current unmet need of the anti-EGFR induced skin diseases market.

Scope of the EGFR Inhibitors-Induced Skin Disorders Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key EGFR Inhibitors-Induced Skin Disorders Companies: Lutris Pharma, Hoth Therapeutics, TWi Biotechnology, Inc., and others

• Key EGFR Inhibitors-Induced Skin Disorders Therapies: LUT-014, HT-001, AC-701 Topical Gel 0.3%, and others

• EGFR Inhibitors-Induced Skin Disorders Therapeutic Assessment: EGFR Inhibitors-Induced Skin Disorders current marketed and EGFR Inhibitors-Induced Skin Disorders emerging therapies

• EGFR Inhibitors-Induced Skin Disorders Market Dynamics: EGFR Inhibitors-Induced Skin Disorders market drivers and EGFR Inhibitors-Induced Skin Disorders market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• EGFR Inhibitors-Induced Skin Disorders Unmet Needs, KOL’s views, Analyst’s views, EGFR Inhibitors-Induced Skin Disorders Market Access and Reimbursement

To know more about EGFR Inhibitors-Induced Skin Disorders companies working in the treatment market, visit @ EGFR Inhibitors-Induced Skin Disorders Clinical Trials and Treatment

Table of Contents

1. EGFR Inhibitors-Induced Skin Disorders Market Report Introduction

2. Executive Summary for EGFR Inhibitors-Induced Skin Disorders

3. SWOT analysis of EGFR Inhibitors-Induced Skin Disorders

4. EGFR Inhibitors-Induced Skin Disorders Patient Share (%) Overview at a Glance

5. EGFR Inhibitors-Induced Skin Disorders Market Overview at a Glance

6. EGFR Inhibitors-Induced Skin Disorders Disease Background and Overview

7. EGFR Inhibitors-Induced Skin Disorders Epidemiology and Patient Population

8. Country-Specific Patient Population of EGFR Inhibitors-Induced Skin Disorders

9. EGFR Inhibitors-Induced Skin Disorders Current Treatment and Medical Practices

10. EGFR Inhibitors-Induced Skin Disorders Unmet Needs

11. EGFR Inhibitors-Induced Skin Disorders Emerging Therapies

12. EGFR Inhibitors-Induced Skin Disorders Market Outlook

13. Country-Wise EGFR Inhibitors-Induced Skin Disorders Market Analysis (2020–2034)

14. EGFR Inhibitors-Induced Skin Disorders Market Access and Reimbursement of Therapies

15. EGFR Inhibitors-Induced Skin Disorders Market Drivers

16. EGFR Inhibitors-Induced Skin Disorders Market Barriers

17. EGFR Inhibitors-Induced Skin Disorders Appendix

18. EGFR Inhibitors-Induced Skin Disorders Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: EGFR Inhibitors-Induced Skin Disorders Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Lutris Pharma, Hoth Therapeutics, TWi Biotechnology

DelveInsight’s “Head and Neck Squamous Cell Carcinomas Patient Pool Analysis, Market Size and Market Forecast APAC – 2034″ report offers an in-depth understanding of the Head and Neck Squamous Cell Carcinomas, historical and forecasted epidemiology as well as the Head and Neck Squamous Cell Carcinomas market trends in the APAC region (India, China, South Korea, Taiwan, and Australia).

To Know in detail about the Head and Neck Squamous Cell Carcinomas market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Head and Neck Squamous Cell Carcinomas Market Forecast

Some of the key facts of the Head and Neck Squamous Cell Carcinomas Market Report:

• The APAC Head and Neck Squamous Cell Carcinomas market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In February 2025, Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing transformative bifunctional therapies for solid tumors, has announced the enrollment of the first patients in FORTIFI-HN01, a pivotal Phase 2/3 trial. This study evaluates ficerafusp alfa in combination with pembrolizumab as a first-line (1L) treatment for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ficerafusp alfa is a first-in-class bifunctional antibody that integrates an epidermal growth factor receptor (EGFR)-targeting monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β).

• In January 2025, Rakuten Medical administered the first dose in its intercontinental Phase III clinical trial evaluating ASP-1929, a photoimmunotherapy treatment for recurrent head and neck squamous cell carcinoma (HNSCC). This multi-center, randomized, open-label study will assess the efficacy of the company’s antibody-dye conjugate, which combines the antibody drug cetuximab with MSD’s leading monoclonal antibody, Keytruda (pembrolizumab).

• In October 2024, MSD (Merck & Co.) has announced that its Phase III KEYNOTE-689 trial evaluating KEYTRUDA (pembrolizumab) for head and neck squamous cell carcinoma (HNSCC) successfully met its primary endpoint of event-free survival (EFS). The randomized, active-controlled, open-label study included 704 treatment-naïve patients with newly diagnosed stage III or IVA resected, locally advanced HNSCC (LA-HNSCC).

• In June 2024, Bicara Therapeutics has shared updated interim results from its ongoing Phase I/Ib clinical trial evaluating ficerafusp alfa for the treatment of human papillomavirus (HPV)-negative recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

• Key Head and Neck Squamous Cell Carcinomas Companies: M.D. Anderson Cancer Center, Sidney Kimmel, Centre hospitalier de, Dana-Farber Cancer Institute, Inovio Pharmaceuticals, Hansoh BioMedical R&D Company, Gilead Sciences, Merck Sharp & Dohme LLC, Exelixis, Sichuan Baili Pharmaceutical Co., Ltd., AVEO Pharmaceuticals, Inc., Benitec Biopharma, Inc., BeiGene, ALX Oncology Inc., Queensland Health, Regeneron Pharmaceuticals, and others

• Key Head and Neck Squamous Cell Carcinomas Therapies: Pembrolizumab, Nivolumab, Durvalumab, Taxotere, CELLECTRA™-5P, HS-20093, Magrolimab, Lenvatinib, Zanzalintinib, BL-B01D1, Ficlatuzumab, BB-401, Tislelizumab, SI-B001, Evorpacept, Pembrolizumab, CMP-001, and others

• The Head and Neck Squamous Cell Carcinomas market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Head and Neck Squamous Cell Carcinomas pipeline products will significantly revolutionize the Head and Neck Squamous Cell Carcinomas market dynamics.

Head and Neck Squamous Cell Carcinomas Overview

Head and Neck Squamous Cell Carcinoma (HNSCC) refers to a group of cancers that originate in the squamous cells lining the mucous membranes of the head and neck region. This includes the oral cavity, throat (pharynx), and voice box (larynx), among other areas. Squamous cells are flat, thin cells that make up the epithelium, the outer layer of the skin and the lining of various organs.

Get a Free sample for the Head and Neck Squamous Cell Carcinomas Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/head-and-neck-squamous-cell-carcinomas-hnsccs-market-size-and-forecast

Head and Neck Squamous Cell Carcinomas Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the APAC countries from 2020-2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Head and Neck Squamous Cell Carcinomas Epidemiology Segmentation:

The Head and Neck Squamous Cell Carcinomas market report proffers epidemiological analysis for the study period 2020-2034 in the APAC region is segmented into:

• Total Prevalence of Head and Neck Squamous Cell Carcinomas

• Prevalent Cases of Head and Neck Squamous Cell Carcinomas by severity

• Gender-specific Prevalence of Head and Neck Squamous Cell Carcinomas

• Diagnosed Cases of Episodic and Chronic Head and Neck Squamous Cell Carcinomas

Download the report to understand which factors are driving Head and Neck Squamous Cell Carcinomas epidemiology trends @ Head and Neck Squamous Cell Carcinomas Epidemiology Forecast

Head and Neck Squamous Cell Carcinomas Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Head and Neck Squamous Cell Carcinomas market or expected to get launched during the study period. The analysis covers Head and Neck Squamous Cell Carcinomas market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Head and Neck Squamous Cell Carcinomas Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Head and Neck Squamous Cell Carcinomas Therapies and Key Companies

• Pembrolizumab: M.D. Anderson Cancer Center

• Nivolumab: Sidney Kimmel

• Durvalumab: Centre hospitalier de

• Taxotere: Dana-Farber Cancer Institute

• CELLECTRA™-5P: Inovio Pharmaceuticals

• HS-20093: Hansoh BioMedical R&D Company

• Magrolimab: Gilead Sciences

• Lenvatinib: Merck Sharp & Dohme LLC

• Zanzalintinib: Exelixis

• BL-B01D1: Sichuan Baili Pharmaceutical Co., Ltd.

• Ficlatuzumab: AVEO Pharmaceuticals, Inc.

• BB-401: Benitec Biopharma, Inc.

• Tislelizumab: BeiGene

• SI-B001: Sichuan Baili Pharmaceutical Co., Ltd.

• Evorpacept: ALX Oncology Inc.

• Pembrolizumab: Queensland Health

• Evorpacept: ALX Oncology Inc.

• CMP-001: Regeneron Pharmaceuticals

Discover more about therapies set to grab major Head and Neck Squamous Cell Carcinomas market share @ Head and Neck Squamous Cell Carcinomas Treatment Landscape

Scope of the Head and Neck Squamous Cell Carcinomas Market Report

• Study Period: 2020-2034

• Coverage: APAC (India, China, South Korea, Taiwan, and Australia)

• Key Head and Neck Squamous Cell Carcinomas Companies: Pembrolizumab, Nivolumab, Durvalumab, Taxotere, CELLECTRA™-5P, HS-20093, Magrolimab, Lenvatinib, Zanzalintinib, BL-B01D1, Ficlatuzumab, BB-401, Tislelizumab, SI-B001, Evorpacept, Pembrolizumab, CMP-001, and others

• Key Head and Neck Squamous Cell Carcinomas Therapies: Pembrolizumab, Nivolumab, Durvalumab, Taxotere, CELLECTRA™-5P, HS-20093, Magrolimab, Lenvatinib, Zanzalintinib, BL-B01D1, Ficlatuzumab, BB-401, Tislelizumab, SI-B001, Evorpacept, Pembrolizumab, CMP-001, and others

• Head and Neck Squamous Cell Carcinomas Therapeutic Assessment: Head and Neck Squamous Cell Carcinomas current marketed and Head and Neck Squamous Cell Carcinomas emerging therapies

• Head and Neck Squamous Cell Carcinomas Market Dynamics: Head and Neck Squamous Cell Carcinomas market drivers and Head and Neck Squamous Cell Carcinomas market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Head and Neck Squamous Cell Carcinomas Unmet Needs, KOL’s views, Analyst’s views, Head and Neck Squamous Cell Carcinomas Market Access and Reimbursement

To know more about Head and Neck Squamous Cell Carcinomas companies working in the treatment market, visit @ Head and Neck Squamous Cell Carcinomas Clinical Trials and Therapeutic Assessment

Table of Contents

1. Head and Neck Squamous Cell Carcinomas Market Report Introduction

2. Executive Summary for Head and Neck Squamous Cell Carcinomas

3. SWOT analysis of Head and Neck Squamous Cell Carcinomas

4. Patient Share (%) Overview at a Glance

5. Head and Neck Squamous Cell Carcinomas Market Overview at a Glance

6. Head and Neck Squamous Cell Carcinomas Disease Background and Overview

7. Head and Neck Squamous Cell Carcinomas Epidemiology and Patient Population

8. Country-Specific Patient Population of Head and Neck Squamous Cell Carcinomas

9. Head and Neck Squamous Cell Carcinomas Current Treatment and Medical Practices

10. Head and Neck Squamous Cell Carcinomas Unmet Needs

11. Head and Neck Squamous Cell Carcinomas Emerging Therapies

12. Head and Neck Squamous Cell Carcinomas Market Outlook

13. Country-Wise Head and Neck Squamous Cell Carcinomas Market Analysis (2020-2034)

14. Head and Neck Squamous Cell Carcinomas Market Access and Reimbursement of Therapies

15. Head and Neck Squamous Cell Carcinomas Market Drivers

16. Head and Neck Squamous Cell Carcinomas Market Barriers

17. Head and Neck Squamous Cell Carcinomas Appendix

18. Head and Neck Squamous Cell Carcinomas Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Head and Neck Squamous Cell Carcinomas Market to Expand Significantly by 2034 Across APAC Region, States DelveInsight Reports | M.D. Anderson Cancer Center, Sidney Kimmel, Centre hospitalier de

The Soft Tissue Sarcoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Soft Tissue Sarcoma pipeline products will significantly revolutionize the Soft Tissue Sarcoma market dynamics.

DelveInsight’s “Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Soft Tissue Sarcoma, historical and forecasted epidemiology as well as the Soft Tissue Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Soft Tissue Sarcoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Soft Tissue Sarcoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Soft Tissue Sarcoma Market Forecast

Some of the key facts of the Soft Tissue Sarcoma Market Report:

• The Soft Tissue Sarcoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In January 2025, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a clinical-stage company specializing in targeted immunotherapeutic drugs, has announced an expansion of its Phase 1 SB101 clinical trial for SON-1010 (IL12-FHAB) in adults with advanced solid tumors. Following the successful completion of monotherapy dose escalation, the study will now include a new cohort to assess SON-1010 in combination with trabectedin (Yondelis®). This expansion aims to evaluate the immune-oncology effects of SON-1010 at the maximum tolerated dose (MTD) of 1200 ng/kg alongside trabectedin, a chemotherapy drug approved for certain advanced soft-tissue sarcomas (STS), with the goal of enhancing local immune response in the tumor microenvironment (TME).

• In October 2024, Adcendo’s antibody-drug conjugate (ADC) candidate has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) and is set to advance into a Phase I/II clinical trial. The Danish immuno-oncology company will initiate the ADCElerate-01 trial, a multi-center, first-in-human Phase I/II study designed to assess the safety and efficacy of ADCE-D01 as a monotherapy in patients with metastatic and unresectable soft tissue sarcoma (STS). ADCE-D01 specifically targets the endocytic receptor uPARAP (Endo180).

• In July 2024, Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company specializing in novel immune-based intratumoral cancer therapies, has announced that the first U.S. patient has been dosed in its Phase 3 trial for metastatic sarcoma (NCT06263231). The study aims to evaluate the efficacy of INT230-6 as a monotherapy compared to the investigator’s choice of three standard systemic chemotherapy options for second- or third-line treatment of metastatic, recurrent, or inoperable soft tissue sarcomas (STS). This superiority trial seeks to both directly eliminate tumors and enhance immune system recognition of cancer cells.

• There were around 42 thousand incident cases of Soft Tissue Sarcoma in the 7MM, in 2021.

• According to Wiltink et al., Soft tissue Sarcoma (STS) are a diverse group of rare tumors of mesenchymal origin with different clinical, histologic and molecular characteristics

• American Association for Thoracic Surgery (AATS) (n.d.), stated that up to 50%of patients with soft tissue sarcoma (STS) develop lung metastasis. Also Nakamura et al. (2021), in a study mentioned that lung metastasis from Soft Tissue Sarcoma (STS) occurs in 20–50% of Soft Tissue Sarcoma (STS) patients

• Key Soft Tissue Sarcoma Companies: Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., and others

• Key Soft Tissue Sarcoma Therapies: Liposomal Annamycin, and others

Soft Tissue Sarcoma Overview

The term soft tissue sarcoma (STS) refers to malignant soft-tissue tumors that may arise anywhere on the body and may consist of a variety of histological subtypes (including lipo Sarcoma, rhabdomyo Sarcoma, synovial Sarcoma, leiomyo Sarcoma, and fibro Sarcoma). As sarcoma may arise virtually anywhere, but the extremity is the most common primary site. Despite progress in multimodality treatment, a large number of patients die each year of soft tissue sarcoma.

Get a Free sample for the Soft Tissue Sarcoma Market Report:

https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market

Soft Tissue Sarcoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Soft Tissue Sarcoma Epidemiology Segmentation:

The Soft Tissue Sarcoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Soft Tissue Sarcoma

• Prevalent Cases of Soft Tissue Sarcoma by severity

• Gender-specific Prevalence of Soft Tissue Sarcoma

• Diagnosed Cases of Episodic and Chronic Soft Tissue Sarcoma

Download the report to understand which factors are driving Soft Tissue Sarcoma epidemiology trends @ Soft Tissue Sarcoma Epidemiological Insights

Soft Tissue Sarcoma Market

The dynamics of the Soft Tissue Sarcoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

“The current pipeline of Soft Tissue Sarcoma is not very rich. A limited number of therapeutic approaches are being evaluated for the patients. As some molecule probably will enter in market in upcoming years, the market is supposed to experience immense growth in future”

Soft Tissue Sarcoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Soft Tissue Sarcoma market or expected to get launched during the study period. The analysis covers Soft Tissue Sarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Soft Tissue Sarcoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Soft Tissue Sarcoma Therapies and Key Companies

• Liposomal Annamycin: Moleculin Biotech, Inc.

To know more about Soft Tissue Sarcoma treatment, visit @ Soft Tissue Sarcoma Medications

Scope of the Soft Tissue Sarcoma Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Soft Tissue Sarcoma Companies: Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., and others

• Key Soft Tissue Sarcoma Therapies: Liposomal Annamycin, and others

• Soft Tissue Sarcoma Therapeutic Assessment: Soft Tissue Sarcoma current marketed and Soft Tissue Sarcoma emerging therapies

• Soft Tissue Sarcoma Market Dynamics: Soft Tissue Sarcoma market drivers and Soft Tissue Sarcoma market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Soft Tissue Sarcoma Unmet Needs, KOL’s views, Analyst’s views, Soft Tissue Sarcoma Market Access and Reimbursement

Discover more about therapies set to grab major Soft Tissue Sarcoma market share @ Soft Tissue Sarcoma Treatment Landscape

Table of Contents

1. Soft Tissue Sarcoma Market Report Introduction

2. Executive Summary for Soft Tissue Sarcoma

3. SWOT analysis of Soft Tissue Sarcoma

4. Soft Tissue Sarcoma Patient Share (%) Overview at a Glance

5. Soft Tissue Sarcoma Market Overview at a Glance

6. Soft Tissue Sarcoma Disease Background and Overview

7. Soft Tissue Sarcoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Soft Tissue Sarcoma

9. Soft Tissue Sarcoma Current Treatment and Medical Practices

10. Soft Tissue Sarcoma Unmet Needs

11. Soft Tissue Sarcoma Emerging Therapies

12. Soft Tissue Sarcoma Market Outlook

13. Country-Wise Soft Tissue Sarcoma Market Analysis (2019–2032)

14. Soft Tissue Sarcoma Market Access and Reimbursement of Therapies

15. Soft Tissue Sarcoma Market Drivers

16. Soft Tissue Sarcoma Market Barriers

17. Soft Tissue Sarcoma Appendix

18. Soft Tissue Sarcoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Soft Tissue Sarcoma Market on Track for Major Expansion by 2032, According to DelveInsight | Moleculin Biotech